Targeted genomic testing of both tumor and matched normal peripheral blood showed somatic mutations in EZH2, MTOR, NF1, RAD21,and TP53 (Table 1), with no germline or somatic mutations in BRCA1/2. The gene discussed is EZH2; the disease is neoplasm.